Related Experiment Video

Updated: Jul 10, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Are there circumstances in which phase 2 study results should be practice-changing?

Marcie R Tomblyn1, J Douglas Rizzo

  • 1Dept. of Hematology, Oncology & Transplantation, University of Minnesota, 420 Delaware St., SE, MMC 480, Minneapolis MN 55455, USA. tombl001@umn.edu

Hematology. American Society of Hematology. Education Program
|November 21, 2007
PubMed

Insights

Understanding phase 2 clinical trial design is crucial for clinicians. This review explores phase 2 study complexities, aiding appropriate application of findings in patient care.

Area of Science:

  • Clinical research methodology
  • Pharmaceutical development
  • Medical statistics

Background:

  • Increasing need for clinical trials due to new pharmaceuticals and treatments.
  • Phase 3 trials are the gold standard for efficacy but are lengthy, costly, and resource-intensive.
  • Rare diseases and indications limit patient recruitment for definitive phase 3 trials.

Purpose of the Study:

  • To emphasize the importance of understanding phase 2 clinical trial design for clinicians.
  • To explore the complexities inherent in phase 2 study designs.
  • To provide guidance on interpreting phase 2 trial results for clinical application.

Main Methods:

  • Review of phase 2 clinical trial design principles.
  • Discussion of unique designs, including randomization possibilities.
  • Analysis of key elements critical for interpreting phase 2 study outcomes.

Main Results:

  • Phase 2 trials present unique design challenges.
  • Randomization can be a component of phase 2 studies.
  • Proper interpretation requires understanding specific design elements.

Conclusions:

  • Clinicians must comprehend phase 2 trial design to effectively use study findings.
  • Phase 2 trials play a vital role when phase 3 is not feasible.
  • This review provides essential insights for interpreting phase 2 clinical trial data.

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...